Table 1.

Trials in perioperative setting

References	Design	Treatment tested	Results
Goss et al10	Phase III	Gefitinib versus placebo	Negative
Altorki et al11	Phase III	Erlotinib versus placebo	Negative
Sun et al12	Retrospective	Chemotherapy	Better outcome for EGFR wild-type compared to EGFR mutation
Janjigian et al13	Single-center No randomized EGFR-mutated patients	Tyrosine kinase inhibitor Chemotherapy	Better outcome with tyrosine kinase inhibitor
Li et al14	Phase II, randomized	Tyrosine kinase inhibitor versus chemotherapy	Negative

Abbreviation: EGFR, epidermal growth factor receptor.